E-mail a Wiley Online Library Link

Edwin M. Posadas, Meghan S. Liel, Virginia Kwitkowski, Lori Minasian, Andrew K. Godwin, Mahrukh M. Hussain, Virginia Espina, Bradford J. Wood, Seth M. Steinberg and Elise C. Kohn A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer Cancer 109

Version of Record online: 1 MAR 2007 | DOI: 10.1002/cncr.22545

Gefitinib treatment for ovarian cancer inhibited the activity of the epidermal growth factor receptor (EGFR) in >50% of the patients in this study. The modulation of EGFR activity was correlated with gefitinib toxicity, and the current results indicated that EGFR inhibition is inadequate as a sole molecular therapeutic target in ovarian cancer.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field